Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push

Pharmaceutical giant Merck is reportedly closing in on a landmark acquisition of biotech company Terns Pharma in an all-cash deal valued at approximately $6 billion, according to a Financial Times report citing insiders familiar with the negotiations. Sources indicate that discussions between the two companies have reached an advanced stage, with a formal agreement potentially just days away.

The move aligns with Merck's broader strategy to strengthen and restructure its oncology portfolio. The company is actively building a dedicated cancer division anchored by its globally recognized immunotherapy drug, Keytruda — one of the best-selling cancer treatments in the world. With Keytruda's patent set to expire in 2028, Merck is working proactively to secure new revenue streams and sustain its dominance in the competitive oncology market.

Terns Pharma, a clinical-stage biopharmaceutical company, has carved out a niche in developing innovative therapies for chronic myeloid leukemia (CML), a type of blood cancer that affects thousands of patients annually. Its specialized pipeline makes it a strategically valuable target for a company like Merck, which is looking to expand its oncology capabilities beyond its flagship treatment.

Market reaction to the news was swift and positive. Shares of Terns Pharma climbed roughly 10% in after-hours trading following the initial report, reflecting strong investor confidence in the deal's potential value. Neither Merck nor Terns Pharma issued an official statement in response to media inquiries at the time of reporting.

If finalized, this acquisition would represent one of the more significant pharmaceutical deals in recent memory, underscoring the growing urgency among major drug companies to diversify their cancer treatment portfolios ahead of upcoming patent cliffs. Industry analysts will be closely watching how this potential merger shapes the future landscape of oncology drug development.